**Slide 1**

Healthcare Associated Infections in 2018
Acute Care Hospitals

Christina Brandeburg, MPH

Epidemiologist

Bureau of Infectious Disease and Laboratory Sciences

Katherine Fillo, Ph.D, MPH, RN-BC

Director of Clinical Quality Improvement

Bureau of Health Care Safety and Quality

Eileen McHale, RN, BSN

Healthcare Associated Infection Coordinator

Bureau of Health Care Safety and Quality

Public Health Council

July 10, 2019

**Slide 2**

**Introduction**

Healthcare-associated infections (HAIs) are infections that patients acquire during the course of receiving treatment for other conditions within a healthcare setting.

HAIs are among the leading causes of preventable death in the United States, affecting 1 in 25 hospitalized patients, accounting for an estimated 722,000 infections and an associated 75,000 deaths during hospitalization.\*

The Massachusetts Department of Public Health (DPH) developed this data update as a component of the Statewide Infection Prevention and Control Program created pursuant to Chapter 58 of the Acts of 2006.

Massachusetts law provides DPH with the legal authority to conduct surveillance, and to investigate and control the spread of communicable and infectious diseases. (MGL c. 111,sections 6 & 7)

DPH implements this responsibility in hospitals through the hospital licensing regulation. (105 CMR 130.000)

Section 51H of chapter 111 of the Massachusetts General Laws authorizes the Department to collect HAI data and disseminate the information publicly to encourage quality improvement. (https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section51H)

\*Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections - an overview. Infect Drug Resist. 2018;11:2321–2333.

**Slide 3**

Introduction

This HAI presentation is the tenth annual Public Health Council update:

It is an important component of larger efforts to reduce preventable infections in health care settings;

It presents an analysis of progress on infection prevention within Massachusetts acute care hospitals; and

It is based upon work supported by state funds and the Centers for Disease Control and Prevention (CDC).

It provides an overview of antibiotic resistance and stewardship activities.

**Slide 4**

Methods

This data summary includes the following statewide measures for the 2018 calendar year (January 1, 2018 – December 31, 2018) as reported to the CDC’s National Healthcare Safety Network (NHSN).

The DPH required measures are consistent with the Centers for Medicare and Medicaid Services quality reporting measures.

Central line associated bloodstream infections (CLABSI) in intensive care units

Catheter associated urinary tract infections (CAUTI) in intensive care units

Specific surgical site infections (SSI); and

Specific facility wide laboratory identified events (LabID).

\*National baseline data for each measure are based on a statistical risk model derived from 2015 national data.

^All data were extracted from NHSN on June 17th, 2019.

**Slide 5**

Measures

The Standardized Infection Ratio (SIR) is calculated by dividing the actual number of infections by the predicted number of infections.

New this year: Standard Utilization Ratio is calculated by dividing the actual number of device days by the predicted number of device days.

**Slide 6**

How to Interpret SIRs and 95% Confidence Intervals (CIs)

What is an SIR?

The standardized infection ratio (SIR) is a summary measure used to track HAIs over time. It compares actual HAI rates in a facility or state with baseline rates derived from aggregate data from NHSN. The CDC adjusts the SIR for risk factors that are most associated with differences in infection rates. In other words, the SIR takes into account that different healthcare facilities treat patients with differences in disease type and severity.

**Slide 7**Massachusetts Central Line-Associated Bloodstream Infection (CLABSI) SIR, by ICU Type
*January 1, 2018-December 31, 2018* Key Findings:

One ICU type, Trauma, experienced a significantly lower number of infections than predicted, based on 2015 national aggregate data.

One ICU type, Burn, experienced a significantly higher number of infections than predicted, based on 2015 national aggregate data.IR, by ICU Type.

**Slide 8**

NEW this Year: Central Line-Associated Bloodstream Infection (CLABSI) Standard Utilization Ratio in Adult and Pediatric ICUs
January 1, 2018-December 31, 2018

CLABSI Standard Utilization Ratio (SUR) by ICU type

Key Findings: Six ICU types experienced a significantly lower number of device days than predicted, based on 2015 national aggregate data:

Burn, Medical (T), Medical (NT), Medical/Surgical (T). Neurosurgical, Trauma

**Slide 9**

CLABSI Adult & Pediatric ICU Pathogens for 2017 and 2018

**January 1, 2017-December 31, 2017**

Jan 1st- Dec 31st, 2017 n =169. gram-negative bacteria 24% ; multiple organisms, 10%; Candida albicans, 11%; yeast/fungus (other), 14%; staphylococcus aureus (not MRSA), 8%; Methicillin resistant staphylococcus aureus, 5%; coagulase negative staphylococcus, 17%; Enterococcus sp., 16%; gram-positive bacteria (other), 6%.

Jan 1st- Dec 31st, 2017 n =165. gram-negative bacteria 24% ; multiple organisms, 10%; Candida albicans, 12%; yeast/fungus (other), 14%; staphylococcus aureus (not MRSA), 8%; Methicillin resistant staphylococcus aureus, 2%; coagulase negative staphylococcus, 16%; Enterococcus sp., 10%; gram-positive bacteria (other), 5%.

**Slide 10**

Massachusetts Central Line-Associated Bloodstream Infection (CLABSI) SIR, by Massachusetts CLABSI SIR in NICUs, by Birth Weight Category *January 1, 2018-December 31, 2018.*

Key Findings

There were no birthweight categories experiencing a significantly higher or lower number of infections than predicted, based on 2015 national aggregate data.

There were 20 CLABSIs reported in Neonatal ICUs.

**Slide 11**

New this Year: Central Line-Associated Bloodstream Infection (CLABSI) Standard Utilization Ratio in Neonatal ICUs January 1, 2018- December 31, 2018.

CLABSI Standard Utilization Ratio (SUR) by Birth Weight Category

Key Findings

Four birthweight categories experienced a significantly lower number of device days than predicted, based on 2015 national aggregate data:

Less than or equal to 750 grams; 751 – 1,000 grams; 1,001 – 1,500 grams; 1,501 – 2,500 grams

**Slide 12**

CLABSI NICU Pathogens for 2017 and 2018

January 1, 2017– December 31, 2017 n=20; Gram-negative bacteria (other) 5%; Staphylococcus aureus not MRSA, 25%; Coagulase negative staphylococcus, 25%; enterococcus sp., 10%.

January 1, 2018– December 31, 2018 n=20; multiple organisms 10%; Staphylococcus aureus not MRSA, 40%; enterococcus sp., 5% ;Coagulase negative staphylococcus, 25%; E.coli, 5%.

**Slide 13**

Key Findings

Between 2015-2017, adult ICUs experienced a significantly lower number of infections than predicted, based on 2015 national aggregate data.

Between 2015-2017, neonatal ICUs saw a decrease in the number of infections

**Slide 14S**

New this Year: State CLABSI SUR

Key Findings

For the past four years, adult and pediatric ICUs experienced a significantly higher number of device days than predicted, based on 2015 national aggregate data.

For the past four years, neonatal ICUs experienced a significantly lower number of device days than predicted, based on 2015 national aggregate data.

**Slide 15**

Massachusetts Catheter-Associated Urinary Tract infection (CAUTI) SIR in Adult and Pediatric ICUs.

CAUTI Standard Infection Ratio (SIR) by IU Type

January 1, 2017-December 31, 2017

Key Findings

Two ICU types experienced a significantly lower number of infections than predicted, based on 2015 national aggregate data: Cardiothoracic; Trauma

No ICUs experienced a significantly higher number of infections than predicted, based on 2015 national aggregate data.

**Slide 16**

New this Year: Catheter-Associated Urinary Tract Infections (CAUTI) in Adult and Pediatric ICUs
January 1, 2018-December 31, 2018
CAUTI Standard Utilization Ratio (SUR) by ICU type

Key Findings

Six ICU types experienced a significantly higher number of device days than predicted, based on 2015 national aggregate data: Cardiac; Cardiothoracic; Medical/Surgical (T); Neurosurgical; Pediatric; Surgical

**Slide 17**

CAUTI Adult & Pediatric ICU Pathogens for 2017 and 2018

Calendar Year 2017 January 1, 2017 – December 31, 2017 n=305

Escherichia coli 34%; Pseudomonas aeruginosa, 13%; Klebsiella pneumoniae, 10%; Coagulase- negative Staphylococcus, 3%; Enterococcus sp.,10%; Gram-positive bacteria (other), 7%; multiple organisms, 8%; Staphylococcus aureus not MRSA), 2%; MRSA. 0.3%.

Calendar Year 2018- January 1, 2018 – December 31, 2018 n=293

Escherichia coli 32%; Pseudomonas aeruginosa, 14%; Klebsiella pneumoniae, 8%; Coagulase- negative Staphylococcus, 5%; Enterococcus sp.,15%; Gram-positive bacteria (other), 4%; Gram-negative other, 4%; multiple organisms, 11%, Staphylococcus aureus not MRSA), 0.3%.

**Slide 18**

State CAUTI SIR

Key Findings

Between 2015-2017, pediatric ICUs saw an increase in the number of infections but in 2018 were no different than predicted, based on 2015 national aggregate data.

There were 9 CAUTIs reported by 10 pediatric ICUs in 2018.

**Slide 19**

New this Year: State CAUTI SUR

Key Findings: For the past four years, adult and pediatric ICUs experienced a significantly higher number of device days than predicted, based on 2015 national aggregate data.

**Slide 20**

Surgical Site Infections (SSI) Coronary Artery Bypass Graft (CABG) SIR and Colon Procedure (COLO) SIR

Key Findings

For the past four years, MA acute care hospitals performing coronary artery bypass graft procedures (CABG) and colon procedures (COLO) experienced the same number of infections as predicted, based on 2015 national aggregate data.

There were 31 CABG SSIs reported in 2018.

There were 184 COLO SSIs reported in 2018.

**Slide 21**

Surgical Site Infections (SSI) Knee Prosthesis (KPRO) SIR and Hip Prosthesis (HPRO) SIR

Key Findings

In 2018, Massachusetts acute care hospitals performing knee prosthesis procedures (KPRO) experienced significantly higher number of infections than predicted, based on 2015 national aggregate data.

There were 77 KPRO SSIs reported in 2018.

There were 81 HPRO SSIs reported in 2018.

**Slide 22**

Surgical Site Infections (SSI) Abdominal Hysterectomy (HYST) SIR and Vaginal Hysterectomy (VHYS) SIR

Key Findings

In 2018, Massachusetts acute care hospitals performing vaginal hysterectomy (VHYS) procedures experienced significantly higher number of infections than predicted, based on 2015 national aggregate data.

There were 25 HYST SSIs reported in 2018.

There were 14 VHYS SSIs reported in 2018

**Slide 23**

SSI Pathogens for 2017-2018 CABG, KPRO, HPRO, HYST, VHYS, COLO

January 1, 2017– December 31, 2017 n=402;

Staphylococcus aureus not MRSA, 12% ; Methicillin-resistant Staphylococcus aureus (MRSA) 5%; coagulase negative staphylococcus, 6%; gram-positive bacteria (other) 7%; Gram-negative bacteria 8%; multiple organisms, 29%; pseudomonas aeruginosa, 1% ;no organism identified, 17%; candida and other yeast /fungus, 2%.

January 1, 2018– December 31, 2018 n=412;

Staphylococcus aureus not MRSA, 13% ; Methicillin-resistant Staphylococcus aureus (MRSA) 6%; coagulase negative staphylococcus, 5%; gram-positive bacteria (other) 7%; Gram-negative bacteria (other) 6%; multiple organisms, 31%; no organism identified, 14%.

**Slide 24**

Statewide SSI Trends by Year 2015-2018

Summary of SSI Results

CABG HPRO COLO: Same as predicted

KPRO, HYST, VHYS: Higher than predicted

**Slide 25**

Laboratory Identified Events (LabID): Clostridium difficile (CDI) SIR

Key Findings

For the past two years, Massachusetts hospitals reporting CDI events experienced significantly lower number of infections than predicted, based on 2015 national aggregate data.

There were 1,904 CDI events reported in 2018.

**Slide 26**

Laboratory Identified Events (LabID): Methicillin-resistant Staphylococcus aureus (MRSA) SIR

Key Findings

For the past four years, Massachusetts acute care hospitals reporting MRSA events experienced significantly lower number of infections than predicted, based on 2015 national aggregate data.

There were 160 MRSA events reported in 2018.

**Slide 27**

Statewide LabID Trends by Year 2015-2018

**Slide 28**

HAI Prevention Activities

External data validation of methicillin resistant Staphylococcus aureus infections conducted at 20 acute care hospitals and Clostridioides difficile infection at 20 long-term care facilities in the fall of 2018 and spring of 2019.

DPH outreach to long-term care facilities to sustain voluntary NHSN Clostridioides difficile reporting; monthly data cleaning reports generated by DPH and provided to facilities beginning in 2019.

Ongoing data sharing with the Neonatal Quality Improvement Collaborative (NeoQIC) to address opportunities for improvement.

Four hemodialysis infection prevention simulation trainings were held for hemodialysis nurses and technicians.

On-site Infection Control Assessment and Response (ICAR) visits expanding from nursing homes and long-term acute care facilities to community health centers.

DPH monitors progress by providing quarterly Data Cleaning Reports and Targeted Assessment for Prevention (TAP) Reports for all hospitals to identify areas where focused infection prevention efforts are needed.

Outreach to hospitals with higher than expected SIRs to ensure the need for improvement has been addressed.

**Slide 29**

Antibiotic Resistance: Scope and Significance of the Issue

Antibiotic or antimicrobial resistance occurs when organisms are able to resist the effects of drugs. Bacteria are not killed by the antibiotic and continue to grow.

Some individuals may be at a greater risk for acquiring a drug resistant infection (individuals with co-morbidities, previous hospitalizations, antibiotic exposures, etc.). However, drug-resistant infections can affect anyone.

Infections with resistant organisms can be difficult to treat, are expensive and are associated with increased mortality.

Inevitably, bacteria are able to adapt to newly developed antibiotics and become resistant.

It is imperative to respond aggressively to prevent resistance and prevent the spread of existing resistant bacteria.

DPH surveils several multi-drug resistant organisms (MDROs) that have been identified as public safety concerns by CDC.

**Slide 30**

Antibiotic Resistance Surveillance: Carbapenem-resistant Enterobacteriaceae in MA

MDRO TYPE: 2016 Enterobacter cloacae, n=22; Klebsiella oxytoca and pneumoniae, n=15; Escherichia coli, n=5; Enterobacter aerogenes, n=8; Total= 50.

2017: Enterobacter cloacae, n=88; Klebsiella oxytoca and pneumoniae, n=78; Escherichia coli, n=5; Enterobacter aerogenes, n=17; Candida auris, n=7; Total= 222.

2018: enterobacter cloacae, n=126; Klebsiella oxytoca and pneumoniae, n=89; Escherichia coli, n=88; Enterobacter aerogenes, n=16; Total= 319.

**Slide 31**

Antibiotic Resistance: MDROs in Massachusetts
Candida auris Example

Confirmed 2017 n= 6; 2018, n=0;

Contact 2017 n=75; 2018, n=10.

Suspect 2017 n=0; 2018, n= 1.

DPH provides epidemiologic investigation support and guidance when specific MDROs are suspected to mitigate any exposure.

Activities include: Provide detailed infection control recommendations; Recommend retrospective and prospective laboratory surveillance; Coordinates colonization screening of close contacts in collaboration with regional laboratory**.**

**Slide 32**

Antibiotic Stewardship Overview

Studies indicate that between 30-50% of antibiotics prescribed in hospitals and between 40-75% of antibiotics prescribed in nursing homes are unnecessary\*.

Improved prescribing practices can help reduce rates of Clostridioides difficile and antibiotic resistance.

Appropriate antibiotic prescribing can improve patient outcomes and reduce healthcare costs.

**Slide 33**

Antibiotic Resistance and Antibiotic Stewardship: MDPH Reporting and Laboratory Testing

Electronic laboratory reporting (ELR) of mandatory MDROs of concern into the Massachusetts Virtual Epidemiologic Network (MAVEN).

Mandatory submission of selected MDRO isolates to the Massachusetts State Public Health Laboratory

for advanced testing here and at our partner ARLN

laboratory, The Wadsworth Center in New York:

Identify novel resistance mechanisms such as genes that code for carbapenemase production or colistin resistance; and Identify Candida auris

**Slide 34**

Antibiotic Resistance and Antibiotic Stewardship: Prevention and Educational Activities

NEW 14 acute care hospitals participate in NHSN antibiotic use (AU) module to better understand trends in antibiotic use and monitor stewardship activities.

2018-2019 Advanced Educational Series entitled “Navigating Infection Control and Antibiotic Stewardship in Long-Term Care” with three “ask the experts” calls.

Collection, monitoring and reporting of facility-level antibiotic use data in long-term care facilities (n=60).

“Bug of the Month” webinar series targeting MDROs of concern for all facility types.

Publication of annual statewide antibiogram.

Provides bug-drug combinations of interest for benchmarking purposes (https://www.mass.gov/service-details/massachusetts-antibiograms)

Engagement with subject matter experts and stakeholders during quarterly statewide HAI/AR Technical Advisory Group (TAG) meetings.

Held the first annual Statewide Antibiotic Stewardship Conference in April, 2019 for long term, long term acute, ambulatory, dialysis and dental care settings.

Slide 35

Antibiotic Resistance and Antibiotic Stewardship: Antibiograms

Graph describing Statewide Staphylococcus aureus Susceptibility Rates – 2017

Slide 36

Antibiotic Resistance and Antibiotic Stewardship:

Next Steps

Awarded a competitive Broad Agency Announcement contract from the CDC to examine antibiotic prescribing in dentistry in MA and to evaluate a feedback intervention for top prescribers.

Incorporate recommendations and findings determined by two national Leadership in Epidemiology, Antimicrobial Stewardship and Public Health (LEAP) fellows, to improve the utility of the statewide antibiogram data and to enhance AS activities in long-term care facilities.

Continue to engage additional infection preventionists in use of MAVEN system for ease in response and containment of MDROs

**Slide 37**

Contact Information

Thank you for the opportunity to present this information today.

Please direct any questions to: Eileen McHale, RN, BSN, Healthcare Associated Infection Coordinator, Bureau of Health Care Safety and Quality, Eileen.mchale@state.ma.us